Literature DB >> 10073951

Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment.

O Salomon1, D M Steinberg, A Zivelin, S Gitel, R Dardik, N Rosenberg, S Berliner, A Inbal, A Many, A Lubetsky, D Varon, U Martinowitz, U Seligsohn.   

Abstract

The inherited thrombophilias--deficiencies of protein C, protein S, and antithrombin III--and the prothrombotic polymorphisms factor V G1691A and factor II G20210A predispose patients toward venous thromboembolism (VTE). The aim of this study was to determine the prevalence of single and combined prothrombotic factors in patients with idiopathic VTE and to estimate the associated risks. The study group consisted of 162 patients referred for work-up of thrombophilia after documented VTE. The controls were 336 consecutively admitted patients. In all subjects factor V G1691A, factor II G20210A, and methylenetetrahydrofolate reductase (MTHFR) C677T were analyzed by specific polymerase chain reactions and restriction enzymes. Activities of antithrombin III and protein C, free protein S antigen, and lupus anticoagulant were determined in a subset of 109 patients who were not receiving oral anticoagulants. The prevalences of heterozygotes and homozygotes for factor V G1691A and factor II G20210A among patients and controls were 40.1% versus 3.9% and 18.5% versus 5.4%, respectively (P=0.0001). The prevalence of homozygotes for MTHFR C677T in patients was 22.8% and in controls, 14.3% (P=0.025). Heterozygous and homozygous factor V G1691A, factor II G20210A, and homozygous MTHFR C677T were found to be independent risk factors for VTE, with odds ratios of 16.3, 3.6, and 2.1, respectively. Two or more polymorphisms were detected in 27 of 162 patients (16.7%) and in 3 of 336 controls (0.9%). Logistic regression analysis disclosed odds ratios of 58.6 (confidence interval [CI], 22.1 to 155.2) for joint occurrence of factor V and factor II polymorphisms, of 35.0 (CI, 14.5 to 84.7) for factor V and MTHFR polymorphisms, and of 7.7 (CI, 3.0 to 19.6) for factor II and MTHFR polymorphisms. Among 109 patients in whom a complete thrombophilic work-up was performed, 74% had at least 1 underlying defect. These data indicate that in most patients referred for evaluation of thrombophilia due to idiopathic VTE, 1 or more underlying genetic predispositions were discernible. The presence of >1 of the prothrombotic polymorphisms was associated with a substantial risk of VTE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10073951     DOI: 10.1161/01.atv.19.3.511

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  26 in total

1.  Partial HELLP syndrome in pregnancy complicated by recurrent deep vein thromboses and palmar skin lesions in a patient with prothrombin gene 20210a mutation and antiphospholipid antibodies: an unusual case.

Authors:  Ronald A Asherson; Cathy Spargo; Jose A Gómez-Puerta
Journal:  Clin Rheumatol       Date:  2007-07-03       Impact factor: 2.980

2.  A case control study on the contribution of factor V-Leiden, prothrombin G20210A, and MTHFR C677T mutations to the genetic susceptibility of deep venous thrombosis.

Authors:  Wassim Y Almawi; Hala Tamim; Raghid Kreidy; Georgina Timson; Elias Rahal; Malak Nabulsi; Ramzi R Finan; Noha Irani-Hakime
Journal:  J Thromb Thrombolysis       Date:  2005-06       Impact factor: 2.300

Review 3.  Phenotypic Heterogeneity in Patients with Homozygous Prothrombin 20210AA Genotype. A paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.

Authors:  David Bosler; Joan Mattson; Domnita Crisan
Journal:  J Mol Diagn       Date:  2006-09       Impact factor: 5.568

4.  Inherited genetic markers for thrombophilia in northeastern Iran (a clinical-based report).

Authors:  Fatemeh Keify; Mohsen Azimi-Nezhad; Narges Zhiyan-Abed; Mojila Nasseri; Mohammad Reza Abbaszadegan
Journal:  Rep Biochem Mol Biol       Date:  2014-04

Review 5.  Thrombophilia, polymorphisms, and vascular disease.

Authors:  T C Sykes; C Fegan; D Mosquera
Journal:  Mol Pathol       Date:  2000-12

6.  Increased Factor V Leiden frequency is associated with venous thrombotic events among young Brazilian patients.

Authors:  Adriano de Paula Sabino; Daniela Amorim Melgaço Guimarães; Daniel Dias Ribeiro; Sabrina Guimarães Paiva; Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho; Ana Paula Fernandes
Journal:  J Thromb Thrombolysis       Date:  2007-03-31       Impact factor: 2.300

Review 7.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

8.  Thrombophilic factors are not the leading cause of thrombosis in Behçet's disease.

Authors:  M Leiba; U Seligsohn; Y Sidi; D Harats; B A Sela; J H Griffin; A Livneh; N Rosenberg; I Gelernter; H Gur; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2004-11       Impact factor: 19.103

9.  Thromboembolic risk in patients with high titre anticardiolipin and multiple antiphospholipid antibodies.

Authors:  Carolyn Neville; Joyce Rauch; Jeannine Kassis; Erika R Chang; Lawrence Joseph; Martine Le Comte; Paul R Fortin
Journal:  Thromb Haemost       Date:  2003-07       Impact factor: 5.249

10.  Impact of thrombophilic genetic factors on pulmonary embolism: early onset and recurrent incidences.

Authors:  Petar Ivanov; Regina Komsa-Penkova; Katia Kovacheva; Yavor Ivanov; Angelina Stoyanova; Ivan Ivanov; Plamen Pavlov; Pavlina Glogovska; Venzislav Nojarov
Journal:  Lung       Date:  2007-12-21       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.